Xencor Inc.'s plan to publicly issue 4,585,000 shares of its common stock is further evidence the clinical-stage US biopharmaceutical company and its product pipeline are maturing.
The NASDAQ-listed biotech Dec. 1 said it filed a preliminary prospectus with the US Securities and Exchange Commission...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
